Arcus Biosciences, Inc. (RCUS)

Arcus Biosciences Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	222	150	127	206	148
Short-Term Investments	759	828	632	803	351
Cash & Short-Term Investments	981	978	759	1,009	499
Cash Growth	0.31%	28.85%	-24.78%	102.20%	-31.52%
Accounts Receivable	11	20	38	39	745
Total Trade Receivables	11	20	38	39	745
Other Current Assets	15	18	34	19	18
Total Current Assets	1,007	1,016	831	1,067	1,262
Net Property, Plant & Equipment	40	47	51	35	32
Long-Term Investments	29	14	107	129	182
Other Long-Term Assets	63	73	106	114	116
Total Assets	1,139	1,150	1,095	1,345	1,592
Accounts Payable	42	18	17	20	10
Unearned Revenue	35	85	91	97	102
Other Current Liabilities	154	123	76	76	54
Total Current Liabilities	231	226	184	193	166
Long-Term Debt	99	48	-	-	-
Other Long-Term Liabilities	178	391	449	495	584
Total Long-Term Liabilities	277	439	449	495	584
Total Liabilities	508	665	633	688	750
Common Stock	2,116	1,617	1,311	1,206	1,118
Additional Paid-in Capital	2,116	1,617	1,311	1,206	1,118
Accumulated Other Comprehensive Income	-	-	-	-7	-1
Retained Earnings	-1,485	-1,132	-849	-542	-275
Shareholders' Equity	631	485	462	657	842
Total Liabilities & Equity	1,139	1,150	1,095	1,345	1,592
Total Debt	99	48	0	0	0
Net Cash (Debt)	882	930	759	1,009	499
Net Cash Growth	-5.16%	22.53%	-24.78%	102.20%	-30.05%
Net Cash Per Share	8.21	10.32	10.26	14.01	6.74
Book Value	631	485	462	657	842
Book Value Per Share	5.88	5.38	6.24	9.13	11.38
Tangible Book Value	631	485	462	657	842
Tangible Book Value Per Share	5.88	5.38	6.24	9.13	11.38

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q